Unknown

Dataset Information

Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sickness.


ABSTRACT:

Objective

Assessment of the safety and efficacy of a 10-day melarsoprol schedule in second stage T.b. rhodesiense patients and the effect of suramin-pretreatment on the incidence of encephalopathic syndrome (ES) during melarsoprol therapy.

Design

Sequential conduct of a proof-of-concept trial (n = 60) and a utilization study (n = 78) using historic controls as comparator.

Setting

Two trial centres in the T.b. rhodesiense endemic regions of Tanzania and Uganda.

Participants

Consenting patients with confirmed second stage disease and a minimum age of 6 years were eligible for participation. Unconscious and pregnant patients were excluded.

Main outcome measures

The primary outcome measures were safety and efficacy at end of treatment. The secondary outcome

SUBMITTER: Kuepfer I 

PROVIDER: S-EPMC3435133 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature